In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guangdong Techpool Bio-Pharma Co. Ltd.

Division of Takeda Pharmaceutical Co. Ltd.
www.techpool.com.cn

Latest From Guangdong Techpool Bio-Pharma Co. Ltd.

Multinationals Score Three Out Four New China Priority Reviews

Eight drugs from foreign multinationals, including Amgen’s Rapatha, Takeda’s Takecab, Sanofi’s Aubagio and UCB’s Cimzia, are among 12 products awarded priority new drug approval reviews in China under a scheme to speed up approvals and patient access that is also benefiting some domestic players.

China Rare Diseases

China Options For Takeda As It Pursues Emerging Markets Buy

Takeda’s recent revelation that it had set aside around $450m for a planned M&A transaction in an undisclosed emerging market has triggered speculation about where and how the company might spend its money. Might China be in the mix?

Commercial China

Takeda’s Planned Emerging Markets Deal: India Yay Or Nay?

Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?

Emerging Markets Deals

Commercial Model Innovation Key To Lowering China Compliance Risks

Balanced scorecards, big data, and platform strategies are among the new tools being employed by pharma companies ramping up compliance and lowering risks in China, where market access remains challenging and pricing pressures persistent. Such commercial model innovation should also improve physician interaction while providing new medical solutions, said executives at a recent RDPAC gathering in Beijing.

BioPharmaceutical China
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register